AnaptysBio, Inc. (NASDAQ:ANAB) had its price objective upped by stock analysts at JMP Securities from $45.00 to $82.00 in a report issued on Tuesday. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. JMP Securities’ target price suggests a potential upside of 17.24% from the company’s current price.
Several other brokerages also recently commented on ANAB. Zacks Investment Research downgraded AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, August 29th. Robert W. Baird initiated coverage on AnaptysBio in a report on Monday, July 10th. They set an “outperform” rating and a $36.00 target price for the company. Credit Suisse Group upped their target price on AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, August 25th. Royal Bank Of Canada initiated coverage on AnaptysBio in a report on Thursday, September 14th. They set an “outperform” rating and a $40.00 target price for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $35.00 target price on shares of AnaptysBio in a report on Tuesday, September 12th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $59.14.
AnaptysBio (NASDAQ ANAB) opened at 69.94 on Tuesday. The firm’s market cap is $1.42 billion. AnaptysBio has a 52 week low of $15.17 and a 52 week high of $74.00. The company has a 50-day moving average of $37.36 and a 200 day moving average of $37.36.
AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $3.45 million. On average, equities analysts predict that AnaptysBio will post ($1.98) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “AnaptysBio, Inc. (ANAB) PT Raised to $82.00 at JMP Securities” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://sportsperspectives.com/2017/10/12/anaptysbio-inc-anab-pt-raised-to-82-00-at-jmp-securities.html.
In related news, major shareholder Holdings A/S Novo sold 70,706 shares of the stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total value of $1,648,156.86. Following the completion of the sale, the insider now directly owns 3,009,949 shares of the company’s stock, valued at approximately $70,161,911.19. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total value of $901,924.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,133,940 shares of company stock valued at $24,223,316.
Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE purchased a new stake in AnaptysBio in the 1st quarter worth about $123,000. DAFNA Capital Management LLC lifted its stake in AnaptysBio by 22.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 1,000 shares in the last quarter. New York State Common Retirement Fund purchased a new stake in AnaptysBio in the 2nd quarter worth about $168,000. TIAA CREF Investment Management LLC purchased a new stake in AnaptysBio in the 1st quarter worth about $227,000. Finally, Teachers Advisors LLC lifted its stake in AnaptysBio by 23.4% in the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 1,807 shares in the last quarter. 71.35% of the stock is owned by hedge funds and other institutional investors.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.